Literature DB >> 11290570

Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases.

C H Rickert1, R Sträter, P Kaatsch, H Wassmann, H Jürgens, B Dockhorn-Dworniczak, W Paulus.   

Abstract

We studied 23 pediatric high-grade astrocytomas by comparative genomic hybridization. Chromosomal imbalances were found in 10 of 10 anaplastic astrocytomas and 11 of 13 glioblastomas and consisted of +1q (43%), +3q (26%), +1p, +2q, +5q (22%), -22q (34%), -6q, -10q (30%), -9q, -11q, -13q, -16q, and -17p (22%). Anaplastic astrocytomas frequently showed +5q (40%), +1q (30%), -22q (50%), -6q, -9q (40%), and -12q (30%); glioblastomas +1q (54%), +3q (38%), +2q, +17q (23%), -6q, -8q, -10q, -13q, and -17p (31%). Minimal common regions mapped to +1q21-41, +3q27-qter, +2q31-32, +5q14-22, -22q12-qter, -10q23-25, -6q25-qter, -9q34.2, -11q14-22, -16q22-qter, and -17p. High-level gains were located on 1q (7 cases), 2q, 7q (4 cases), 3q (3 cases), 9, 17q (2 cases), 4q, 8q, 18, and 20q (1 case). A significantly shorter survival was found for anaplastic astrocytomas showing +1q (P: < 0.05), MIB-1 proliferation index >25% (P: < 0.001) and glioblastomas (P: < 0.05). Compared with adult cases, +1p, +2q, and +21q as well as -6q, -11q, and -16q were more frequent in pediatric malignant astrocytomas. Among the latter +5q, -6q, -9q, -12q, and -22q were characteristic for pediatric anaplastic astrocytomas and +1q, +3q, +16p, -8q, and -17p for pediatric glioblastomas. Our results show that chromosomal aberrations differ between pediatric anaplastic astrocytomas and glioblastomas as well as between pediatric and adult high-grade astrocytomas, supporting the notion of a different genetic pathway. Furthermore, gains of chromosomal material on 1q might be correlated with a worse prognosis in pediatric anaplastic astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290570      PMCID: PMC1891902          DOI: 10.1016/S0002-9440(10)64103-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades.

Authors:  K Ichimura; E E Schmidt; A Miyakawa; H M Goike; V P Collins
Journal:  Genes Chromosomes Cancer       Date:  1998-05       Impact factor: 5.006

2.  Chromosomal aberrations detected by comparative genomic hybridization (CGH) in human astrocytic tumors.

Authors:  M Maruno; T Yoshimine; A K Muhammad; H Ninomiya; A Kato; T Hayakawa
Journal:  Cancer Lett       Date:  1999-01-08       Impact factor: 8.679

3.  The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.

Authors:  I F Pollack; R L Hamilton; S D Finkelstein; J W Campbell; A J Martinez; R N Sherwin; M E Bozik; S M Gollin
Journal:  Cancer Res       Date:  1997-01-15       Impact factor: 12.701

4.  Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.

Authors:  E W Newcomb; H Cohen; S R Lee; S K Bhalla; J Bloom; R L Hayes; D C Miller
Journal:  Brain Pathol       Date:  1998-10       Impact factor: 6.508

5.  Mutations and immunohistochemistry of p53 and proliferation markers in astrocytic tumors of childhood.

Authors:  D Schiffer; P Cavalla; A Di Sapio; M T Giordana; A Mauro
Journal:  Childs Nerv Syst       Date:  1995-09       Impact factor: 1.475

6.  PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.

Authors:  Y Tohma; C Gratas; W Biernat; A Peraud; M Fukuda; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  1998-07       Impact factor: 3.685

7.  Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas.

Authors:  K Harada; T Nishizaki; S Ozaki; H Kubota; H Ito; K Sasaki
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

8.  Clinically distinct subgroups of glioblastoma multiforme studied by comparative genomic hybridization.

Authors:  R G Weber; C Sommer; F K Albert; M Kiessling; T Cremer
Journal:  Lab Invest       Date:  1996-01       Impact factor: 5.662

9.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506

10.  MIB-1 labeling index in nonpilocytic astrocytoma of childhood: a study of 101 cases.

Authors:  D M Ho; T T Wong; C Y Hsu; L T Ting; H Chiang
Journal:  Cancer       Date:  1998-06-15       Impact factor: 6.860

View more
  39 in total

1.  Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.

Authors:  Manila Antonelli; Francesca Romana Buttarelli; Antonietta Arcella; Sumihito Nobusawa; Vittoria Donofrio; Hiroko Oghaki; Felice Giangaspero
Journal:  J Neurooncol       Date:  2010-02-21       Impact factor: 4.130

Review 2.  Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies.

Authors:  Mandeep S Tamber; Krishan Bansal; Muh-Lii Liang; Todd G Mainprize; Bodour Salhia; Paul Northcott; Michael Taylor; James T Rutka
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

Review 3.  Molecular genetics of pediatric central nervous system tumors.

Authors:  Nicole J Ullrich; Scott L Pomeroy
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

4.  The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.

Authors:  Kaisorn L Chaichana; Hasan Zaidi; Courtney Pendleton; Matthew J McGirt; Rachel Grossman; Jon D Weingart; Alessandro Olivi; Alfredo Quiñones-Hinojosa; Henry Brem
Journal:  Neurol Res       Date:  2011-09       Impact factor: 2.448

5.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.

Authors:  Barbara S Paugh; Chunxu Qu; Chris Jones; Zhaoli Liu; Martyna Adamowicz-Brice; Junyuan Zhang; Dorine A Bax; Beth Coyle; Jennifer Barrow; Darren Hargrave; James Lowe; Amar Gajjar; Wei Zhao; Alberto Broniscer; David W Ellison; Richard G Grundy; Suzanne J Baker
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

6.  Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood.

Authors:  Valentina Vladimirova; Thomas Mikeska; Andreas Waha; Niels Soerensen; Jingying Xu; Patrick C Reynolds; Torsten Pietsch
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

Review 7.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

Review 8.  Initial management of childhood brain tumors: neurosurgical considerations.

Authors:  Farideh Nejat; Mostafa El Khashab; James T Rutka
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

9.  Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.

Authors:  Alberto Broniscer; Suzanne J Baker; Clinton F Stewart; Thomas E Merchant; Fred H Laningham; Paula Schaiquevich; Mehmet Kocak; E Brannon Morris; Raelene Endersby; David W Ellison; Amar Gajjar
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

10.  Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation.

Authors:  Samantha J Ward; Katherine Karakoula; Kim P Phipps; William Harkness; Richard Hayward; Dominic Thompson; Thomas S Jacques; Brian Harding; John L Darling; David G T Thomas; Tracy J Warr
Journal:  J Neurooncol       Date:  2010-01-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.